- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
New Systemic Treatments for Prurigo Nodularis
Author(s):
Key Takeaways
- Prurigo nodularis diagnosis is challenging due to symptom overlap with other pruritic conditions and absence of specific tests.
- Increased prevalence is noted in patients with atopic dermatitis and other specific subtypes.
Melodie Young, MSN, A/GNP-C, discusses how the FDA-approved systemic treatments for prurigo nodularis, dupilumab and nevolizumabnemolizumab, differ in their mechanisms of action—dupilumab targeting IL-4 and IL-13, and nevolizumabnemolizumab targeting IL-31—and highlights their similar efficacy in reducing pruritus and lesion size, while also considering differences in safety profiles and treatment considerations.
Video Player is loading.
Video content above is prompted by the following:
5. Two systemic treatments are now FDA-approved for prurigo nodularis: dupilumab and nevolizumabnemolizumab. Can you briefly discuss these two 2 agents, including similarities/differences as well as efficacy and safety?
Related Videos
Utility of Molecular Testing in Skin Cancer Risk Assessment
Limitations and Challenges in Skin Cancer Staging Systems
Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis
Mechanism of Action Differences Among IL-17 Inhibitors
The Role of IL-17 in Psoriasis Pathogenesis
Navigating the Boxed Warning for the JAK Inhibitor Class
Personalized Photoprotection Based on Patient Factors
Impact of Oxidative Stress on Skin Health and the Utility of Antioxidants
Laboratory Monitoring for JAK Inhibitors and Key Takeaways
Options for Eyebrow and Eyelash Regrowth in a 32-Year-Old Female With Alopecia Areata
Related Content
